Analysis of ten studies indicates the NETest is an accurate (>95%) biomarker suitable for clinical use in NET disease management, exhibiting utility as an IVD to establish a diagnosis and monitor therapeutic efficacy.
The NETest PPQ–Peptide Receptor Radionuclide Therapy Predictor Quotient–exhibits over 97% accuracy in predicting positive response to PRRT for metastatic/inoperable NETs in real time.
Neuroendocrine Neoplasia Diagnosis: mRNA biomarker NETest exhibits 3-5 times greater accuracy than Chromogranin A
NETest, a multigenomic mRNA biomarker exhibiting ~99% accuracy in NEN disease identification; is far more accurate than CgA (19–33%) and should be considered the biomarker standard of care.
NETest demonstrates a sensitivity of over 95% and a specificity of over 90% in detecting neuroendocrine cancer, making it four times more precise than CgA.